Pharma Business of HIV/AIDS, STDs & STIs

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to increase till $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015. The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, a stringent government regulation for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

    Related Conference of Pharma Business of HIV/AIDS, STDs & STIs

    June 09-10, 2020

    10th European Epidemiology and Public Health Congress

    Istanbul, Turkey
    July 22-23, 2020

    10th World Congress on Rare Diseases and Orphan Drugs

    Barcelona, Spain
    August 19-20, 2020

    European Summit on HIV, STD and STIs

    Milan, Italy
    September 28-29, 2020

    13th Global Infections Conference

    Singapore
    October 5-6, 2020

    12th Euro-Global Conference on Infectious Diseases

    Vienna, Austria
    November 05-06, 2020

    9th Asia Pacific STD and Infectious Diseases Congress

    Tokyo, Japan
    February 15-16, 2021

    8th International Congress on Infectious Diseases

    London, UK
    February 22-23, 2021

    4th Global Experts Meeting on Infectious Diseases

    Singapore City, Singapore

    Pharma Business of HIV/AIDS, STDs & STIs Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in